Nazima Pathan
YOU?
Author Swipe
View article: Pediatric critical illness endotypes reveal distinct outcomes and immune pathways shared across cause of illness
Pediatric critical illness endotypes reveal distinct outcomes and immune pathways shared across cause of illness Open
Characterisation of shared patterns of immune responses in critical illnesses, known as “endotypes”, may have therapeutic significance. Using unsupervised k-means clustering of genome-wide gene expression profiling, we derived, validated a…
View article: STARSHIP Part 2: Disturbed Pressure Reactivity Duration and Magnitude in Pediatric Severe Traumatic Brain Injury—Outcome Implications
STARSHIP Part 2: Disturbed Pressure Reactivity Duration and Magnitude in Pediatric Severe Traumatic Brain Injury—Outcome Implications Open
Cerebral autoregulation (CA) plays a critical role in maintaining cerebral blood flow (CBF) amid fluctuations in systemic blood pressure, with dysfunction increasing vulnerability to secondary brain injury, particularly after traumatic bra…
View article: Dynamic versus fixed cerebral perfusion pressure targets in paediatric traumatic brain injury: a STARSHIP analysis
Dynamic versus fixed cerebral perfusion pressure targets in paediatric traumatic brain injury: a STARSHIP analysis Open
Action Medical Research for Childrens' Charity and Addenbrookes Charitable Trust (UK Grant number-GN2609).
View article: Exploring the Association Between Myocardial Infarction and Cognitive Decline: A Narrative Review
Exploring the Association Between Myocardial Infarction and Cognitive Decline: A Narrative Review Open
The association between cognitive impairment (CI) and myocardial infarction (MI) has been highlighted in recent years. Several studies have reported an increased incidence of cognitive decline (CD) following MI, emphasizing the need for ea…
View article: Enhanced diagnosis of severe bacterial and fungal respiratory infection in children using a rapid syndromic array—case report
Enhanced diagnosis of severe bacterial and fungal respiratory infection in children using a rapid syndromic array—case report Open
The pathogens included on molecular arrays and interpretation by a multidisciplinary team are crucial in providing value to PICU diagnostic services. Molecular arrays have the potential to enhance early pathogen-specific diagnosis of LRTI …
View article: Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study
Host gene expression signatures to identify infection type and organ dysfunction in children evaluated for sepsis: a multicentre cohort study Open
Australian Government Medical Research Future Fund Genomic Health Futures Mission, Children's Hospital Foundation Queensland, Brisbane Diamantina Health Partners, Emergency Medicine Foundation, Gold Coast Hospital Foundation, Far North Que…
View article: A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer Open
These results support the use of encorafenib plus binimetinib combination treatment as a new treatment option in people with BRAF V600E-mutant metastatic NSCLC. The side effects of encorafenib plus binimetinib in this study were similar to…
View article: Use of selective gut decontamination in critically ill children: PICnIC a pilot RCT and mixed-methods study
Use of selective gut decontamination in critically ill children: PICnIC a pilot RCT and mixed-methods study Open
Background Healthcare-associated infections are a major cause of morbidity and mortality in critically ill children. In adults, data suggest the use of selective decontamination of the digestive tract may reduce the incidence of healthcare…
View article: Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study)
Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study) Open
Objective Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resista…
View article: Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial Open
Medical Research Council and National Institute of Health Research.
View article: Microbial Cellulases: Isolation, Characterization and Application in Textile Industry
Microbial Cellulases: Isolation, Characterization and Application in Textile Industry Open
Denim stone wash fabric is in high demand in youngsters. Stone washing is carried out by pumice stone to create such fabric. Major disadvantages of stone washing are that it reduces the life span of jeans as it weakens the fabric, it is ov…
View article: Rapid Detection of Antimicrobial Resistance Genes in Critically Ill Children Using a Custom TaqMan Array Card
Rapid Detection of Antimicrobial Resistance Genes in Critically Ill Children Using a Custom TaqMan Array Card Open
Bacteria are identified in only 22% of critically ill children with respiratory infections treated with antimicrobial therapy. Once an organism is isolated, antimicrobial susceptibility results (phenotypic testing) can take another day. A …
View article: Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study Open
Background Early rehabilitation and mobilisation encompass patient-tailored interventions, delivered within intensive care, but there are few studies in children and young people within paediatric intensive care units. Objectives To explor…
View article: Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England
Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England Open
Objective To describe hospital admissions associated with SARS-CoV-2 infection in children and adolescents. Design Cohort study of 3.2 million first ascertained SARS-CoV-2 infections using electronic health care record data. Setting Englan…
View article: Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non–Small-Cell Lung Cancer
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Non–Small-Cell Lung Cancer Open
PURPOSE The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF V600E/K -mutant metastatic melanoma. We evaluated the effic…
View article: IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C)
IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C) Open
This repository contains the scRNA-Seq data (including TCR-Seq and BCR-Seq data) set used in the manuscript titled "IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C)". T…
View article: IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C)
IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C) Open
This repository contains the scRNA-Seq data (including TCR-Seq and BCR-Seq data) set used in the manuscript titled "IL-18 couples innate and adaptive immune cell activation in acute multisystem inflammatory syndrome in children (MIS-C)". T…
View article: Evaluation of Autoantibody Binding to Cardiac Tissue in Multisystem Inflammatory Syndrome in Children and COVID-19 Vaccination–Induced Myocarditis
Evaluation of Autoantibody Binding to Cardiac Tissue in Multisystem Inflammatory Syndrome in Children and COVID-19 Vaccination–Induced Myocarditis Open
Importance Cardiac dysfunction and myocarditis have emerged as serious complications of multisystem inflammatory syndrome in children (MIS-C) and vaccines against SARS-CoV-2. Understanding the role of autoantibodies in these conditions is …
View article: Data from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Data from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors Open
Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with …
View article: Supplementary Information from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Supplementary Information from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors Open
Table S1. Patient flow by dose group Table S2. PK parameters of utomilumab following multiple dosing Figure S1. Partial response in a patient with anaplastic thyroid carcinoma (utomilumab 3.6 mg/kg + pembrolizumab 2 mg/kg) at cycle 4 versu…
View article: Data from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Data from Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors Open
Purpose: This phase Ib study (NCT02179918) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of utomilumab, a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137 in combination with …